Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000557997 | SCV000640812 | uncertain significance | Nemaline myopathy 2 | 2018-09-21 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine with glutamic acid at codon 1792 of the NEB protein (p.Lys1792Glu). The lysine residue is moderately conserved and there is a small physicochemical difference between lysine and glutamic acid. This variant is present in population databases (rs541641039, ExAC 0.09%). This variant has not been reported in the literature in individuals with NEB-related disease. ClinVar contains an entry for this variant (Variation ID: 465613). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000622837 | SCV000741637 | uncertain significance | Inborn genetic diseases | 2016-08-01 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000557997 | SCV001453494 | uncertain significance | Nemaline myopathy 2 | 2020-09-16 | no assertion criteria provided | clinical testing |